Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03694249 · ClinicalTrials.gov registry record · Phase 2

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

A Phase 2 study of Malignant Solid Tumor, sponsored by Vanderbilt-Ingram Cancer Center.

Active
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT03694249 is a Phase 2 study of Malignant Solid Tumor that is active but no longer recruiting, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 30 participants, below the 164-participant average among 8 other Malignant Solid Tumor trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03694249, a Phase 2 study of Malignant Solid Tumor, is active but no longer recruiting, sponsored by Vanderbilt-Ingram Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.

Conditions Studied

Malignant Solid Tumor

Interventions

  • OTHER Placebo
  • DRUG Ifetroban Sodium

Study Locations (1)

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-12-12
Est. Completion 2026-04
Phase Phase 2

Sponsor

Vanderbilt-Ingram Cancer Center

189 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03694249

The ClinicalTrials.gov registry entry for NCT03694249 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 8 other Malignant Solid Tumor trials with a reported enrollment target (82% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03694249 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT03694249 about?

NCT03694249 is a clinical study titled "Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence". This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on the...

What is the current status of trial NCT03694249?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-12-12. Estimated completion is 2026-04.

What conditions does trial NCT03694249 study?

This clinical trial studies the following conditions: Malignant Solid Tumor.

What interventions are being tested in trial NCT03694249?

The interventions under investigation include: Placebo (OTHER), Ifetroban Sodium (DRUG).

Who is sponsoring clinical trial NCT03694249?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03694249 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Solid Tumor

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.